US appeals court rules in favour of BRCA gene patenting
This article was originally published in SRA
Executive Summary
A US appeals court has ruled that Myriad Genetics' composition patent claims covering the BRCA1 and BRCA2 genes are valid, determining that the isolated DNA molecules do not exist in nature and are, therefore, patentable subject matter1.